<DOC>
	<DOCNO>NCT01136395</DOCNO>
	<brief_summary>This project comprise immunological virological analysis within prospective clinical study Rituximab ( Rtx ) -treated blood group incompatible living donor ( LD ) renal transplant recipient compare blood group compatible LD recipient without Rtx induction , live donor compare deceased donor renal transplant recipient treat tacrolimus ( Tacr ) /mycophenolate sodium ( MPS ) . Aim project assess short- long-term effect immunosuppressive therapy ( Rtx induction ) living donation immunological histological parameter graft outcome viral replication ( BK , JC , CMV , EBV ) potential improve long-term graft outcome enable risk estimation virus disease .</brief_summary>
	<brief_title>Impact Rituximab Induction Living Donation Immunoregulation Virus Control Renal Transplantation</brief_title>
	<detailed_description>Objective . Blood group incompatible ( ABOi ) LD renal transplantation represent recognize treatment modality Germany . In set , ethical consideration allow detailed study short- long-term immunological virological effect Rtx induction therapy , include sequential protocol biopsy . In proposed project perform analyse peripheral blood , iliac lymph node protocol biopsy . Protocol biopsies routinely obtain 3 12 month posttransplant Universities Giessen Freiburg . In prospective , open pilot study , immunological parameter graft outcome control polyomavirus , EBV CMV replication compare RTx-treated ABOi LD renal transplant recipient ( n=25-30 , group 1 ) blood group compatible LD renal transplant recipient without Rtx induction ( n=25-30 , group 2 ) otherwise comparable immunosuppressive treatment ( MPS Tacr , switch Tacr-MR ( modified release ) within 2 week posttransplant ; follow-up 5 year ) . The analysis do DD renal transplant recipient treat Tacr ( switch Tacr-ME ) MPS ( n=25-30 , group 3 ) . This study design allow analyze impact live donation immunoregulation virus control ( group 2 versus 3 ) . Background . There grow evidence humoral mechanism play major role chronic allograft dysfunction , show significantly associate de-novo formation donor-specific HLA antibody . However , B cell appear act humoral response graft may play significant role T-cell mediate antidonor response due role effective antigen-presenting cell . This suggested fact Rtx effective primarily T-cell mediate disease rheumatoid arthritis multiple sclerosis . Hypothesis/specific aim . We hypothesize Rtx induction may alter immunoregulation short- long-term renal transplantation potential improve long-term outcome . Graft protective effect Rtx induction may provide B cell depletion result effect humoral well T cell response , also alter response B cell repopulation . Possible negative effect Rtx polyomavirus CMV control well protective effect EBV replication , de-novo monoclonal gammopathy regulation lymphoma growth factor ( IL-6 , IL-10 ) analyze . Furthermore , B cell subset analysis peripheral blood probably associate impact Rtx B cell depletion graft drain iliac lymph node may enable u establish optimize Rtx dosage thereby allow successful ABOi renal transplantation without currently observe 15 % drop out . Preliminary result . We perform clinical study show predictive power immune parameter regulatory anti-Fab autoantibody , sCD30 , CD4 helper activity , CD4 cell IL-4 IL-10 response graft outcome . The long-term effect Rtx induction therapy live donation parameter analyze . Previously , find patient risk polyomavirus nephropathy may recognize early posttransplant sequential rt-PCR assessment polyomavirus replication urine . Sequential rt-PCR test polyomavirus replication urine plasma use analyze effect Rtx induction polyomavirus control . Proposed method . Immune parameter analyze mainly pretransplant , 3 month 1 , 2 5 year posttransplant . Flow cytometry ( include regulatory T cell , B cell subset , expression cytokine receptor , costimulatory adhesion molecule ) , mitogen-stimulated allogeneic cocultures , protein-A plaque assay ( B cell response , CD4 helper activity ) , intracellular cytokine analysis CD4+ CD8+ T cell , B cell monocytes , rt-PCR virological study ( BK , JC , CMV , EBV ) immunofluorescent stain iliac lymph node ( obtained time transplantation ) protocol biopsy use . Donor-specific antibody detect use lymphocytotoxicity , HLA class I II ELISA Luminex assay . Donor-specificity confirm T- B-cell crossmatch donor cell . Regulatory IgG IgA anti-Fab autoantibody , neopterin sCD30 assess ELISA . Expected result . We expect Rtx induction show impact immunological parameter graft outcome , de-novo posttransplant antidonor HLA antibody formation . This pilot study may allow improve long-term kidney graft outcome recipient immunologic risk parameter virtue patient-tailored immunosuppressive therapy . In ABOi renal transplantation , study may prevent current 15 % drop rate allow optimized Rtx dosage base intend dose response analysis ( B cell subset analysis blood graft drain lymph node ) . Furthermore , study allow risk estimation Rtx administration respect CMV polyomavirus replication , may provide clue concern protection EBV replication posttransplant lymphoproliferative disease . The latter point great clinical importance patient enhance PTLD risk EBV negative recipient EBV positive graft .</detailed_description>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Denovo kidney transplantation Deceased donor ( blood group compatible ) living donor ( blood group incompatible / blood group compatible ) First , second third renal transplant Immunized nonimmunized graft recipient Age recipients 18 year older Negative pregnancy test transplantation Contraindications use Tacr MPS , respectively Contraindications use Rtx group ABOi LD transplant Chronic hepatitis B , C HIV infection Recurrent infectious disease Previous hepatitis B , prophylactic antiviral therapy use Previous tuberculosis Hemoglobin &lt; 8,5g/dl , thrombocytes &lt; 80.000/ul leucocyte &lt; 3000/ul Previous vaccination live vaccine &lt; 4 week pretransplant Significant enterogastric disease diverticulitis ( contraindicate MPS treatment ) Children adolescent ( age le 18 year ) Pregnancy breastfeed woman Refusal effective contraception woman capable bear child Combined transplantation simultaneous islet/kidney transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Living Donor</keyword>
	<keyword>ABO Incompatible Transplantation</keyword>
	<keyword>Immunology</keyword>
	<keyword>CMV</keyword>
	<keyword>EBV</keyword>
	<keyword>Polyomavirus</keyword>
</DOC>